Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Download All
Get an expert’s take on the evolving role of immune checkpoint inhibitors in managing advanced gastric and esophageal cancers with this program, which features a series of ClinicalThought™ commentaries on emerging clinical data, managing immune-related adverse events, and key biomarkers of response.
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Axel Grothey Headshot
Axel Grothey, MD
Steven Maron, MD

Module

Gain expert perspectives on leveraging immune checkpoint inhibitors to optimally manage advanced gastric/GEJ cancers including identifying patients most likely to benefit, managing immune-related adverse events, and insights on emerging data with combination regimens.

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Axel Grothey Headshot Axel Grothey, MD Steven Maron, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: August 9, 2019 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings